Participated · Crowdfunding · Jul 2026

Founded in 2024 and based in Blagnac, Positive Aviation is developing the FF72 by converting ATR 72 airframes into amphibious water-bombers equipped with twin scoop floats. The demonstrator program has reached a manufacturing milestone with delivery of the first of two 17m composite scoop floats built by Multiplast, and flight testing of the FF72-X1 is planned for early 2027. The company projects certification in 2028 and in-service availability for the 2029 fire season. Positive Aviation says the FF72 can deliver 8 tonnes per drop and estimates the aircraft will cost approximately €35M, about half the price of a Canadair, while serving a worldwide market it estimates at nearly 400 aircraft. Financially, the startup employs 20 staff, has raised €8M from institutional investors plus €1.4M via crowdfunding, and is preparing a further €40M round to industrialize production and establish maintenance and training capabilities. It also has a launch customer contract with Bridger Aerospace for 10 planes and 10 options, representing a potential €700M in revenue.

Led · Equity · Apr 2026

Founded in 2019, HYCCO designs and manufactures carbon-fiber bipolar plates, a key component for hydrogen fuel-cell systems. The company operates a 450 m² production site with an annual capacity of 10,000 pieces and holds five patents protecting its technology. HYCCO targets markets such as long-endurance drones and is co-developing a hydrogen propulsion system with H3 Dynamics, with commercialization planned for 2026. It reports 18 customers in 10 countries and derives 68% of its revenue from exports. Financially, HYCCO grew revenue from €200k in 2023 to €763k in 2025 and aims for €1.5M in 2026, with a large portion of that revenue already secured. The company intends to use the funds from the current €1M Wiseed campaign to scale production capacity and support commercial roll-out.

Led · Equity · Dec 2025

Be-Energy operates a 1,300 m² facility in Avignon where its 17-person team regenerates or reconditions lead, lithium, NiMH and other batteries for clients ranging from automotive fleets to JC Decaux’s advertising panels. The company has developed proprietary equipment, including its patented PTS 800 lithium battery machine that will be showcased at CES 2025, and a lead-battery tester capable of running seven diagnostics in seven seconds while feeding an AI-driven knowledge base. With 2024 revenue of €2.3 million, Be-Energy already reaches 52 countries through licensed sites and subsidiaries, and it is rolling out master-franchise agreements in markets such as India. Domestically, management plans to open five company-owned regeneration centres in Paris, Nantes, Lille, Lyon and Toulouse by 2026, creating roughly 15 new jobs. The firm believes regenerated batteries can match new units in performance at half the cost, addressing a vast, environmentally driven market that spans vehicles, e-bikes, construction tools, backup generators and urban street furniture.

Led · Equity · Sep 2025

eBikeLabs is a Grenoble-based startup that develops a comprehensive software solution designed to be integrated directly by e-bike manufacturers. Its platform controls motor assistance, security features and fleet management, delivering an out-of-the-box digital layer for connected bicycles. The company employs 12 people and generated €985 000 in revenue last year, remaining profitable for the past two years. eBikeLabs reports that its technology is already deployed on more than 50 000 bikes, demonstrating early market traction. The firm now plans to accelerate commercialization of its platform, adapt the software to additional hardware configurations and deepen its R&D efforts. These initiatives are intended to broaden its customer base within the rapidly growing e-mobility sector.

Led · Equity · Sep 2025

Founded in 2020, Priothera is a Franco-Irish biotechnology company based in Saint-Louis with 25 employees. Its lead asset is mocravimod, an oral sphingosine-1-phosphate receptor modulator now advancing toward a Phase 3 clinical trial for the treatment of hematological malignancies. The company’s goal is to commercialize mocravimod by 2030 and establish it as a standard-of-care in blood cancer therapy. Priothera has already secured €63 million in funding since inception to support clinical development. To propel the Phase 3 program, it has initiated additional fundraising efforts, including a €3 million crowdfunding campaign on Wiseed and a broader €40 million Series B round. The firm recently bolstered its non-dilutive financing with a €1.70 million i-Nov 2025 grant from Bpifrance and €685,000 from the Région Grand Est through the European Regional Development Fund. These funds are intended to accelerate international clinical trials and expand the company’s development pipeline.